Autopsy report · NCT00704938

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

“Terminated due to withdrawal of support from our collaborator.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 2 months before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 3 years after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

National Institutes of Health Clinical Center (CC)

Sponsor type

US National Institutes of Health

Conditions

Kidney Cancer; Melanoma (Skin); Unspecified Adult Solid Tumor, Protocol Specific

Interventions

aldesleukin; anti-p53 T-cell receptor-transduced peripheral blood lymphocytes; autologous dendritic cell-adenovirus p53 vaccine; filgrastim; cyclophosphamide; fludarabine phosphate

Participants

3

Sites

1

Countries

United States

Trials that died the same way

• Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study
  “terminated due to administrative reasons.” (80% match in meaning)
• Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
  “Terminated due to the sponsor's decision.” (75% match in meaning)
• A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease
  “Terminated due to strategic business decision.” (75% match in meaning)
• Pilot Study Evaluating the Use of Nasal Carbon Dioxide for the Treatment of Cluster Headache
  “Terminated at the request of the financial sponsor.” (74% match in meaning)
• A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma
  “Terminated due to safety concerns.” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.